Skip to Content

Mela-Know-More

2024
Team Members:
  • Stephanie Anyanwu
  • Ethan Chang
  • Ella Holtermann
  • Sharanya Parvathaeni
  • Sabahat Rahman
  • Smriti Srikanth
  • Tina Tian
  • Brendon Young
Advisors:
  • Dr. Elizabeth Logsdon
Sponsors:
  • Luo Gu, PhD
  • Vito Rebecca, PhD
  • Meg Gerstenblith, MD
  • Joel C. Sunshine, MD, PhD, MS
  • Todd Murphy
  • Yun Chen, PhD
  • Aditi Sriram

Abstract:

Melanoma, the fifth most common form of cancer in the United States, is presented as pigmented lesions due to cancerous pigment-producing skin cells. Despite over 100,000 new cases predicted in 2024, the screening process remains inefficient. Dermatologists visually inspect suspicious lesions for subjective characteristics to determine whether to take a biopsy, which introduces racial bias into the examination process and results in 83.3-96.7% of skin biopsies being unnecessary. This leads to heavy burdens for patients, dermatologists, and healthcare systems in terms of time, cost, and associated physical risks. Hence, there exists a substantial need for an objective screening method for melanoma to reduce the rate of unnecessary skin biopsies performed. Various studies have shown a well-established correlation between melanoma lesions and higher tissue stiffness. Here is proposed a method of quantifying skin tissue stiffness in situ to aid in objectifying melanoma screening process.

Team Video

Read the Johns Hopkins University privacy statement here.

Accept